Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory Multiple myeloma

NCT Number	NCT07032129
Lead Sponsor	Essen Biotech
Conditions	Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma, Refractory
Enrollment	60 participants
Start Date	2025-04-29
Primary Completion	2027-12-10 (estimated)
Study Completion	2028-12-28 (estimated)
Updated on ClinicalTrials.gov	2025-06-22